Effects of Meal Size on the Release of GLP-1 and PYY After Roux-en-Y Gastric Bypass Surgery in Obese Subjects With or Without Type 2 Diabetes

Obesity Surgery

Volumn 24, Issue 11, 2014, Pages 1969-1974

  Yan, Wen ^a   Polidori, David ^a   Yieh, Lynn ^a   Di, Jianing ^a   Wu, Xiaodong ^a   Moreno, Veronica ^a   Li, Lina ^a   Briscoe, Celia P ^a   Shankley, Nigel ^a   Dohm, G Lynis ^b   Pories, Walter J ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Bariatric surgery; GLP 1; Meal size; Obese; PYY

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 (9 36); GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; PEPTIDE YY; PEPTIDE YY [3-36]; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CALORIC INTAKE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INTESTINE; LEAN BODY WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PORTION SIZE; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; ROUX EN Y GASTRIC BYPASS; ROUX Y ANASTOMOSIS; STOMACH BYPASS; SURGICAL PATIENT; TEST MEAL; WEIGHT REDUCTION; BLOOD; COMPLICATION; FOOD; MIDDLE AGED; OBESITY, MORBID; POSTOPERATIVE PERIOD;

ADULT; ANASTOMOSIS, ROUX-EN-Y; DIABETES MELLITUS, TYPE 2; FEMALE; FOOD; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MIDDLE AGED; OBESITY, MORBID; PEPTIDE YY; POSTOPERATIVE PERIOD;

EID: 84917684969     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-014-1316-9     Document Type: Article

References (25)

1. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.
2. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339–50.
3. Wickremesekera K, Miller G, Naotunne TD, et al. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg. 2005;15:474–81.
4. le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007;246:780–5.
5. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–39.
6. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144:5149–58.
7. le Roux CW, Bloom SR. Peptide YY, appetite and food intake. Proc Nutr Soc. 2005;64:213–6.
8. Neary NM, Small CJ, Druce MR, et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology. 2005;146:5120–7.
9. le Roux CW, Batterham RL, Aylwin SJ, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology. 2006;147:3–8.
10. Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609–13.
11. Beckman LM, Beckman TR, Earthman CP. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review. J Am Diet Assoc. 2010;110:571–84.
12. Vincent RP, le Roux CW. Changes in gut hormones after bariatric surgery. Clin Endocrinol (Oxf). 2008;69:173–9.
13. Ashrafian H, le Roux CW. Metabolic surgery and gut hormones—a review of bariatric entero-humoral modulation. Physiol Behav. 2009;97:620–31.
14. Lugari R, Dell’Anna C, Ugolotti D, et al. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes. Horm Metab Res. 2000;32:424–8.
15. Reed MA, Pories WJ, Chapman W, et al. Roux-en-Y gastric bypass corrects hyperinsulinemia implications for the remission of type 2 diabetes. J Clin Endocrinol Metab. 2011;96:2525–31.
16. Onaga T, Zabielski R, Kato S. Multiple regulation of peptide YY secretion in the digestive tract. Peptides. 2002;23:279–90.
17. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology. 1985;89:1070–7.
18. Rijkelijkhuizen JM, McQuarrie K, Girman CJ, et al. Effects of meal size and composition on incretin, alpha-cell, and beta-cell responses. Metabolism. 2010;59:502–11.
19. Bagger JI, Knop FK, Holst JJ, et al. Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes Obes Metab. 2011;13:965–71.
20. Korner J, Bessler M, Cirilo LJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab. 2005;90:359–65.
21. Borg CM, le Roux CW, Ghatei MA, et al. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg. 2006;93:210–5.
22. Laferrere B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007;30:1709–16.
23. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003;349:941–8.
24. Pannacciulli N, Le DS, Salbe AD, et al. Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. Neuroimage. 2007;35:511–7.
25. Ma X, Bruning J, Ashcroft FM. Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons. J Neurosci. 2007;27:7125–9.